IA
GNMX

IFP Advisors’s Aevi Genomic Medicine Inc GNMX Stock Holding History

IFP Advisors’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-500
Closed -$1K – 4023
2018
Q3 		$1K Hold
500
– – ﹤0.01% 3771
2018
Q2 		$1K Hold
500
– – ﹤0.01% 3826
2018
Q1 		$1K Hold
500
– – ﹤0.01% 3716
2017
Q4 		$1K Hold
500
– – ﹤0.01% 3767
2017
Q3 		$1K Hold
500
– – ﹤0.01% 4009
2017
Q2 		$1K Hold
500
– – ﹤0.01% 4006
2017
Q1 		$1K Hold
500
– – ﹤0.01% 3908
2016
Q4 		$3K Sell
500
-30
-6% -$158 ﹤0.01% 3575
2016
Q3 		$3K Hold
530
– – ﹤0.01% 3508
2016
Q2 		$3K Buy
+530
New +$2.78K ﹤0.01% 3400
2016
Q1 		– Sell
-30
Closed – – 3788
2015
Q4 		$0 Buy
+30
New +$204 ﹤0.01% 3844

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

IFP Advisors's GNMX Position: Q4 2018 in Review

IFP Advisors sold out of Aevi Genomic Medicine Inc (GNMX) in Q4 2018, closing a stake of 500 shares — an estimated $1K sold.

IFP Advisors first reported a position in GNMX in Q4 2015 and held it in 11 quarters. The position peaked at $3K in Q4 2016. 38 funds tracked by Wall St. Rank hold GNMX as of Q4 2018.

  • IFP Advisors reported no remaining Aevi Genomic Medicine Inc position as of Q4 2018 after selling out during the quarter.
  • IFP Advisors sold 500 Aevi Genomic Medicine Inc shares in Q4 2018, an estimated $1K.
  • IFP Advisors first reported a position in Aevi Genomic Medicine Inc in Q4 2015 and held it in 11 quarters.
  • IFP Advisors's Aevi Genomic Medicine Inc position peaked at $3K in Q4 2016.
  • 38 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2018.

Based on IFP Advisors's 13F filing for Q4 2018, filed 23 Jan 2019.